Last reviewed · How we verify
NCT05189054
Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
trial testing stereotacitic body radiation therapy in Stereotactic Body Radiation Therapy in 40 participants. Currently enrolling.
30 April 2025
Quick facts
| Lead sponsor | Peking University Third Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 May 2022 |
| Primary completion | 30 April 2025 |
| Estimated completion | 30 April 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- stereotacitic body radiation therapy
Conditions studied
- Stereotactic Body Radiation Therapy — all drugs for Stereotactic Body Radiation Therapy →
- Irradiation; Reaction — all drugs for Irradiation; Reaction →
- Thoracic Tumor — all drugs for Thoracic Tumor →
- Recurrent Cancer — all drugs for Recurrent Cancer →
Sponsor
Peking University Third Hospital
Who can join
Adults 18 to 80, any sex, with Stereotactic Body Radiation Therapy or Irradiation; Reaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The reirradiation of thoracic tumor is difficult. The possibility of surgery or re course radiotherapy is very small. In the NCCN guideline, only systemic treatment is recommended. However, the effective rate of systemic treatment is low. SBRT has the characteristics of high dose in tumor target area and low dose in surrounding normal tissues. In theory, SBRT is more conducive to the protection of normal tissues and can potentially be used in the salvage treatment of recurrent lesions after radiotherapy. Even so, SBRT is still controversial in the rescue treatment of recurrent lung cancer after radiotherapy, especially for "ultral-central" lesions close to mediastinal structures (such as bronchus, esophagus and large blood vessels), which have a high probability of fatal side effects. However, a few studies on the application of SBRT in the reirradiation for ultral-central lung cancer have shown acceptable safety and efficacy. Generally speaking, there are few studies on SBRT in the treatment of recurrent ultral-central tumor with limited data. The purpose of this study is to further evaluate the efficacy and toxicities of SBRT in the treatment of recurrent ultral-central tumors after radiotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05189054
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stereotactic Body Radiation Therapy
Currently open trials in the same condition.
- NCT04940936 — Shared Decision Making on Radiation Dose for Lung Malignancies · NA · recruiting
- NCT04512846 — Comparison of Efficacy in SBRT of Large HCC With or Without TACE · recruiting
- NCT03253536 — Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients Wi · recruiting
Other Peking University Third Hospital trials
Trials by the same sponsor.
- NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
- NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
- NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
- NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
- NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05189054 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
- Last refreshed: 27 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05189054.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing